Neoadjuvant chemoradiotherapy of GEM +S-1 for resectable pancreatic cancer : Phase II study

Neoadjuvant chemoradiotherapy of GEM +S-1 for resectable pancreatic cancer : Phase II study - NACRT of GS for resectable pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032361

Enrollment

Registered

2018-05-01

Start date

2018-04-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Neoadjuvant chemoradiotherapy with gemcitabine and S-1 followed by surgery and adjuvant therapy of oral S-1 .

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Resectable pancreatic cancer without Stage IA cases 2) no prior therapy 3) 20 years-old <= 4) ECOG performance status of 0 or 1 5) Adequate organ function 8) Written informed consen

Exclusion criteria

Exclusion criteria: 1) Severe drug allergy 2) pulmonary fibrosis or interstitial pneumonitis 3) Uncontrolled watery diarrhea 4) Active infection 5) Severe disease 6) Pregnant females, possibly pregnant females

Design outcomes

Primary

Measure	Time frame
Overall survuval	—

Countries

Japan

Contacts

Public ContactYasuhiro Yabushita

Yokohama City University School of Medicine Department of Gastroenterological Surgery

yabu23@yokohama-cu.ac.jp045-787-2650

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026